Shotgun proteomic antigen identification

A method for rapid screening and identification of eluted hydrophilic and/or lipophilic antigenic components present in a tissue or whole organ from a subject exposed to the tissue or whole organ, comprising the steps of:

• (a) obtaining a first biological sample comprising blood from the subject who has been exposed to antigenic components of the tissue or whole organ;
• and obtaining a second biological sample comprising the tissue or whole organ from the subject;
• (b) attaching immunoglobulins, or fragments thereof, isolated from the first biological sample to a column, thereby creating an affinity chromatography column comprising the immobilized immunoglobulins, or fragments thereof;
• (c) extracting hydrophilic and lipophilic antigenic components from a second biological sample by a two-step extraction process comprising, sequentially exposing the second biological sample to:
• (i) a hydrophilic solubilization solution selected from the group consisting of 3-(Benzyl-dimethylammonio)propanesulfonate (NDSB-256);
• 3-[N,N-Dimethyl(3-myristoylaminopropyl)amino]-propanesulfonate (ASB-14);
• 3[N,N-Dimethyl-(3-palmitoylaminopropyl)ammonio]-propanesulfonate (ASB-16);
• 4-n-Octylbenzoylamido-propyl-dimethylammoniosulfobetaine (ASB-C80);
• 3-(N,N-Dimethyloctylammonio)-propanesulfonate inner salt (SB3-8);
• N-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (SB3-10);
• N-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (SB3-14);
• 3-(N,N Dimethylpalmitylammonio)propanesulfonate (SB3-16);
• and 3-(N,N-Dimethyloctadecyl-ammonio)propanesulfonate (SB3-18);
• and
• (ii) a lipophilic solubilization solution selected from the group consisting of 3-(Benzyldimethyl-ammonio)propanesulfonate (NDSB-256) and 1% (w/v) n-dodecyl-β-D-maltoside (NDSB-L);
• 3-[N,N-Dimethyl(3-myristoylaminopropyl)amino]propanesulfonate (ASB-14);
• 3-[N,N-Dimethyl-(3-palmitoyl-amino-propyl)ammonio]propanesulfonate (ASB-16);
• 4-n-Octylbenzoylamido-propyl-dimethylammoniosulfobetaine (ASB-C80);
• 3-(N,N-Dimethyloctylammonio)propanesulfonate inner salt (SB3-8);
• N-Decyl-N,N-dimethyl-3-ammonio-1-propane-sulfonate (SB3-10);
• N-Tetradecyl-N,N-dimethyl-3-ammonio-1-propane-sulfonate (SB3-14);
• 3-(N,N Dimethylpalmitylammonio)-propanesulfonate (SB3-16);
• and 3-(N,N-Dimethyloctadecylammonio)propanesulfonate (SB3-18),
• wherein the lipophilic antigenic components are extracted by exposing the tissue or whole organ to a concentration of a lipophilic solubilization solution that is at least 5-fold greater than the concentration of the hydrophilic solubilization solution used to extract the hydrophilic antigenic components;
• (d) exposing the extracted hydrophilic and lipophilic antigenic components prepared from step (c) to the affinity chromatography column comprising the immobilized immunoglobulins, or fragments thereof from the first biological sample from steps (a) and (b), under conditions that allow antigenic components in the extracted hydrophilic and lipophilic antigenic components from step (c) to be bound or not be bound to the immunoglobulins, or fragments thereof on the affinity chromatography column;
• (e) washing the affinity chromatography column to remove non-antigenic components that did not bind to the affinity chromatography column;
• (f) eluting the bound antigenic components from the immobilized immunoglobulins, or fragments thereof on the affinity chromatography column, wherein eluting comprises exposing the bound antigenic components to a step-wise change or a gradient change in eluent properties selected from the group consisting of pH, salt concentration, acetonitrile concentration, and a combination thereof;
• and
• (g) identifying the eluted antigenic components prepared by step (f) by mass spectrometry, wherein the eluted antigenic components are selected from the group consisting of proteins, carbohydrates, and lipids.